Notícias e Atividades da Alnylam Pharmaceuticals

Alnylam Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Alnylam Pharmaceuticals é uma empresa listada sob o símbolo ALNY (US).

Veja o organograma con seus 37 executivos principais

Biografias mais buscadas da Alnylam Pharmaceuticals

• Yvonne Greenstreet, Chief Executive Officer and Director
• Amy Schulman, Chairman of the Board
• Michael Bonney, Director

Recentes movimentos de executivos em Alnylam Pharmaceuticals

• Phillip Sharp, Director, se aposentou  (Notícia publicada em 6 de março de 2025).

Criar um alerta
para seguir os movimentos de executivos da Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Alnylam Pharmaceuticals

• Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosi
• Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
• AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Pati
• Alnylam Issues 2024 Corporate Responsibility Report
• Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the
• Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
• Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
• Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopath
• Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
• Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
• View more press releases Close

Redes sociais sobre Alnylam Pharmaceuticals

• Alnylam Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Alnylam Pharmaceuticals na LinkedIn, Twitter e YouTube